Open Access

CD147 blockade as a potential and novel treatment of graft rejection

  • Authors:
    • Jing Luan
    • Yu Zhao
    • Yang Zhang
    • Jinlin Miao
    • Jia Li
    • Zhi‑Nan Chen
    • Ping Zhu
  • View Affiliations

  • Published online on: August 9, 2017     https://doi.org/10.3892/mmr.2017.7201
  • Pages: 4593-4602
  • Copyright: © Luan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cluster of differentiation (CD)147 is highly involved in the T cell activation process. High CD147 expression is observed on the surfaces of activated T cells, particularly CD4+ T cells. In organ transplantation, it is important to prevent graft rejection resulting from the excessive activation of T cells, particularly CD4+ T cells, which exhibit a key role in amplifying the immune response. The present study aimed to investigate the effects of CD147 blockade in vitro and in vivo and used a transplant rejection system to assess the feasibility of utilizing CD147 antibody‑based immunosuppressant drugs for the treatment of graft rejection. The effects of CD147 antibodies were evaluated on lymphocyte proliferation stimulated by phytohemagglutinin or CD3/CD28 magnetic beads and in a one‑way mixed lymphocyte reaction (MLR) system in vitro. For the in vivo analysis, an allogeneic skin transplantation mouse model was used. CD147 antibodies were effective against lymphocytes, particularly CD4+T lymphocytes, and were additionally effective in the one‑way MLR system. In the allogeneic skin transplantation mouse model, the survival of transplanted skin was extended in the CD147 antibody‑treated group. Furthermore, the level of inflammatory cell infiltration in transplanted skin was reduced. CD147 blockade decreased the serum levels of interleukin (IL)‑17 and the proportions of peripheral blood CD4+ and CD8+ memory T cells. The data demonstrated that CD147 blockade suppressed skin graft rejection, primarily by suppressing CD4+T and memory T cell proliferation, indicating that CD147 exhibits great potential as a target of immunosuppressant drugs.

Related Articles

Journal Cover

October-2017
Volume 16 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Luan J, Zhao Y, Zhang Y, Miao J, Li J, Chen ZN and Zhu P: CD147 blockade as a potential and novel treatment of graft rejection. Mol Med Rep 16: 4593-4602, 2017.
APA
Luan, J., Zhao, Y., Zhang, Y., Miao, J., Li, J., Chen, Z., & Zhu, P. (2017). CD147 blockade as a potential and novel treatment of graft rejection. Molecular Medicine Reports, 16, 4593-4602. https://doi.org/10.3892/mmr.2017.7201
MLA
Luan, J., Zhao, Y., Zhang, Y., Miao, J., Li, J., Chen, Z., Zhu, P."CD147 blockade as a potential and novel treatment of graft rejection". Molecular Medicine Reports 16.4 (2017): 4593-4602.
Chicago
Luan, J., Zhao, Y., Zhang, Y., Miao, J., Li, J., Chen, Z., Zhu, P."CD147 blockade as a potential and novel treatment of graft rejection". Molecular Medicine Reports 16, no. 4 (2017): 4593-4602. https://doi.org/10.3892/mmr.2017.7201